Tibolone and low-dose continuous combined hormone treatment: Vaginal bleeding pattern, efficacy and tolerability

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 114, Issue 12, 2007, Pages 1522-1529

  Hammar, M L ^a   Van De Weijer, P ^b   Franke, H R ^c   Pornel, B ^d   Von Mauw, E M J ^e   Nijland, E A ^f,g  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b GELRE HOSPITALS   (Netherlands)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

^d Brussels Menopause Center   (Belgium)

^e NV ORGANON   (Netherlands)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

E2 NETA; Menopause; Tibolone; Tolerability; Vaginal bleeding

Indexed keywords

ESTRADIOL PLUS NORETHISTERONE ACETATE; TIBOLONE;

ADULT; ARTICLE; BREAST TENDERNESS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EUROPE; FEMALE; HORMONAL THERAPY; HOT FLUSH; HUMAN; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MASTALGIA; MENOPAUSAL SYNDROME; MULTICENTER STUDY; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; VAGINA ATROPHY; VAGINA BLEEDING; WEIGHT GAIN;

AGED; CONTRACEPTIVES, ORAL, SYNTHETIC; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HOT FLASHES; HUMANS; METRORRHAGIA; MIDDLE AGED; NORETHINDRONE; NORPREGNENES;

EID: 35948990369     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2007.01537.x     Document Type: Article

References (37)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002 288 : 321 33.
2. McKinlay SM, Brambilla DJ, Posner JG. The normal menopausal transition. Maturitas 1992 14 : 103 15.
3. Rodstrom K, Bengtsson C, Lissner L, Milsom I, Sundh V, Bjorkelund C. A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century. Menopause 2002 9 : 156 61.
4. Porter M, Penney GC, Russell D, Russell E, Templeton A. A population based survey of women's experience of the menopause. Br J Obstet Gynaecol 1996 103 : 1025 8.
5. Smith CL, O'Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 2004 25 : 45 71.
6. Kloosterboer HJ. Tissue-selectivity: the mechanism of action of tibolone. Maturitas 2004 48 (Suppl 1 S30 40.
7. De Gooyer ME, Deckers GH, Schoonen WG, Verheul HA, Kloosterboer HJ. Receptor profiling and endocrine interactions of tibolone. Steroids 2003 68 : 21 30.
8. Huber J, Palacios S, Berglund L, Hänggi W, Sathanandan SM, Christau S, et al. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. BJOG 2002 109 : 886 93.
9. Hammar M, Christau S, Nathorst-Böös J, Rud T, Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998 105 : 904 11.
10. De Gooyer ME, Overklift Vaupel Kleyn GT, Smits KC, Ederveen AGH, Verheul HAM, Kloosterboer HJ. Tibolone: a compound with tissue specific inhibitory effect on sulfatase. Mol Cell Endocrinol 2001 183 : 55 62.
11. Lundström E, Christow A, Kersemaekers W, Svane G, Azavedo E, Söderqvist G, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002 186 : 717 22.
12. Ettinger B. Meeting the evolving therapeutic needs of postmenopausal women. J Bone Miner Metab 2000 18 : 299 304.
13. Purdie DW. Selective estrogen receptor modulation: HRT replacement therapy? Br J Obstet Gynaecol 1997 104 : 1103 5.
14. Hill DA, Weiss NS, LaCroix AZ. Adherence to postmenopausal hormone therapy during the year after the initial prescription. Am J Obstet Gynecol 2000 182 : 270 6.
15. Genazzani AR, Schneider HPG, Nijland EA. The European Menopause Survey 2005: what do women think right now about menopause and HRT? Climacteric 2005 8 (Suppl 2 96.
16. von Holst T, Lang E, Winkler U, Keil D. Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone. Maturitas 2002 43 : 265 75.
17. Delmas PD, Confavrex E, Garnero P, Fardellone P, de Vernejoul MC, Cormier C, et al. A combination of low doses of 17β-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women. Osteoporos Int 2000 11 : 177 87.
18. Archer DF, Dorin MH, Heine W, Nanavati N, Arce JC. Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate. Obstet Gynecol 1999 94 : 323 9.
19. Johnson JV, Davidson M, Archer D, Bachmann G. Postmenopausal uterine bleeding profiles with two forms of continuous combined hormone replacement therapy. Menopause 2002 9 : 16 22.
20. Al-Azzawi F, Wahab M, Habiba M, Akkad A, Mason T. Continuous combined hormone replacement therapy compared with tibolone. Obstet Gynecol 1999 93 : 258 64.
21. Dören M, Rübig A, Coelingh Bennink JT, Holzgreve W. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. Menopause 1999 6 : 299 306.
22. Baracat EC, Barbosa IC, Giordano MG, Haidar MA, Marinho RM, Menegocci JC, et al. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability. Climacteric 2002 5 : 60 9.
23. Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 2005 51 : 21 8.
24. Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 2002 87 : 16 23.
25. Moore RA. Livial: a review of clinical studies. Br J Obstet Gynecol 1999 106 (Suppl 19 1 21.
26. Samsioe G. Hormone replacement therapy: aspects of bleeding problems and compliance. Int J Fertil Menopausal Stud 1996 41 : 11 15.
27. Karakoc B, Erenus M. Compliance considerations with hormone replacement therapy. Menopause 1998 5 : 102 6.
28. Heikkinen JE, Vaheri RT, Ahomaki SM, Kainulainen PM, Viitanen AT, Timonen UM. Optimizing continuous-combined hormone replacement therapy for postmenopausal women: a comparison of six different treatment regimens. Am J Obstet Gynecol 2000 182 : 560 7.
29. Hickey M, Fraser IS. The causes and management of endometrial breakthrough bleeding. Reprod Med Rev 2001 9 : 153 71.
30. Van de Weijer PHM, Barentsen R, de Vries M, Kenemans P. Relationship of estradiol levels to breakthrough bleeding during continuous combined hormone replacement therapy. Obstet Gynecol 1999 93 : 551 7.
31. King RJ, Whitehead MI. Assessment of the potency of orally administered progestins in women. Fertil Steril 1986 46 : 1062 6.
32. Archer DF, Navarro FJ, Leslie S, Mirkin S. Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone and 17β-estradiol on vascular endothelial growth factor isomers 121 and 165 in Ishikawa cells. Fertil Steril 2004 81 : 165 70.
33. Seki N, Kodama J, Hashimoto I, Hongo A, Yoshinouchi M, Kudo T. Thrombospondin-1 and 2 messenger RNA expression in normal and neoplastic endometrial tissues: correlation with angiogenesis and prognosis. Int J Oncol 2001 19 : 305 10.
34. Landgren MB, Coeling Bennink HJT, Helmond FA, Engelen S. Dose response analysis of effects of tibolone on climacteric symptoms. BJOG 2002 109 : 1109 14.
35. Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce JC. Initial 17β-estradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000 95 : 726 31.
36. Archer DF, Hendrix S, Gallagher C, Rymer J, Skouby S, Ferenczy A, et al. Endometrial effects of tibolone: results from the Tibolone Histology of the Endometrium and Breast Endpoints Study (THEBES). J Clin Endocrinol Metab 2007 92 : 911 18.
37. Davis SR. The effects of tibolone on mood and libido. Menopause 2002 9 : 162 70.